The use of antidepressant drugs: Some reasons for concern

International Journal of Risk and Safety in Medicine

Volumn 11, Issue 4, 1998, Pages 271-274

  Fava, Giovanni A ^a,b   Tomba, Elena ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; LEVODOPA; SEROTONIN UPTAKE INHIBITOR;

DEPRESSION; DRUG DEPENDENCE; DRUG MARKETING; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; FOLLOW UP; HYPOTHESIS; LONG TERM CARE; PARKINSON DISEASE; RECURRENCE RISK; REVIEW; SYMPTOMATOLOGY; TREATMENT INDICATION;

EID: 0032460335     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. C. Medawar, The antidepressant Web, Int. J. Risk Safety Med. 10 (1997), 75-126.
2. G. Dukes. Editorial, Int. J. Risk. Safety Med. 10 (1997), 67-69.
3. J. Zajecka, K. Tracy and S. Mitchell, Discontinuation symptoms after treatment with serotonin reuptake inhibitors. A literature review, J. Clin. Psychiatry 58 (1997), 291-297.
4. J.F. Rosenbaum, M. Fava, S.L. Hood, R.C. Ashcroft and W.B. Krebs, Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial, Biol. Psychiatry 44 (1998), 77-87.
5. D.G. Grahame-Smith, "Keep on taking the tablets": pharmacological adaptation during long-term drug therapy, Br. J. Clin. Pharmacol. 44 (1997), 227-238.
6. G.A. Fava, Do antidepressant and antianxiety drugs increase chronicity in affective disorders?, Psychother. Psychosom. 61 (1994), 125-131.
7. G.A. Fava, Holding on: depression, sensitization by antidepressant drugs, and the prodigal experts, Psychother. Psychosom. 64 (1995), 57-61.
8. R.J. Baldessarini, Risks and implications of interrupting maintenance psychotropic drug therapy, Psychother. Psychosom. 63 (1995), 137-141.
9. G.A. Fava, Potential sensitizing effects of antidepressant drugs on depression, CNS Drugs (in press).
10. A.M. Young and A.J. Goudie, Adaptive processes regulating tolerance to behavioral effects of drugs, in: Psychopharmacology, F.E. Bloom and D.J. Kupfer, eds, Raven Press, New York, 1995.
11. G.A. Fava, All our dreams are sold, Psychother. Psychosom. 67 (1998), 191-193.
12. J.C. Kramer, D.F. Klein and M. Fink, Withdrawal symptoms following discontinuation of imipramine therapy. Am. J. Psychiatry 118 (1961), 549, 550.
13. T. Suppes, R.J. Baldessarini, N. Motohashi, L. Tondo and A.C. Vignera, Special treatment issues: maintaining and discontinuing psychotropic medications, Mod. Probl. Pharmacopsychiatry 25 (1997), 235-254.
14. F.K. Goodwin, The biology of recurrence, J. Clin. Psychiatry 50(4) (1989), 40-44.
15. S.B. Levy, The Antibiotic Paradox. How Miracle Drugs are Destroying the Miracle, Plenum, New York, 1992.
16. S. Fahn, Levodopa-induced neurotoxicity, CNS Drugs 8 (1997), 376-393.
17. M.R. Sears, Long-acting beta agonists, tachyphylaxis, and corticosteroids, Chest 109 (1996), 862-864.